checkAd

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Relief Therapeutics Holding SA / Key word(s): Miscellaneous
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

21.11.2022 / 07:00 CET/CEST


APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Geneva, Switzerland, November 21, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (“APR”) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.

APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease. APR's short movie, Forward – Live your best life, was nominated as a finalist among more than 200 participants by a jury of international experts comprised of patient associations, health care professionals and film makers.

“With our campaign Live your best life!, we highlight the emotional journey lived by PKU families, their doubts about the future and the difficulties in juggling with a strict diet and protein substitutes, together with their eagerness to pursue their full potential in life,” said Paolo Galfetti, Chief Executive Officer of APR, whose real-life story of becoming a father of a child with PKU inspired the movie. Paolo Galfetti commented on APR's work for his first child, Riccardo, born with the condition: “Knowing these products may be helpful for patients and families who live with this rare disease, as for health care professionals, is our biggest reward. I’m proud of working with passionate people and of the results we achieved together. Being so involved both personally and professionally makes me even more proud of my son and the determined and energetic young man he became.”

Seite 1 von 4


Nachrichtenquelle: EQS Group AG
 |  247   |   |   

Schreibe Deinen Kommentar

Disclaimer

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival Relief Therapeutics Holding SA / Key word(s): Miscellaneous APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival 21.11.2022 / 07:00 CET/CEST APR Applied Pharma …

Nachrichten des Autors

352 Leser
304 Leser
240 Leser
228 Leser
220 Leser
1032 Leser
824 Leser
756 Leser
688 Leser
684 Leser
1632 Leser
1236 Leser
1220 Leser
1056 Leser
1032 Leser
2389 Leser
2343 Leser
2237 Leser
2225 Leser
2172 Leser